These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3410101)

  • 1. Initial trial of slow-release testosterone microspheres in hypogonadal men.
    Burris AS; Ewing LL; Sherins RJ
    Fertil Steril; 1988 Sep; 50(3):493-7. PubMed ID: 3410101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
    Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
    J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
    Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compounded percutaneous testosterone gel: use and effects in hypogonadal men.
    Cutter CB
    J Am Board Fam Pract; 2001; 14(1):22-32. PubMed ID: 11206690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
    Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: monitoring of testosterone replacement therapy with testosterone buciclate.
    Tschöp M; Behre HM; Nieschlag E; Dressendörfer RA; Strasburger CJ
    Clin Chem Lab Med; 1998 Apr; 36(4):223-30. PubMed ID: 9638347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex hormone-binding globulin changes with androgen replacement.
    Plymate SR; Leonard JM; Paulsen CA; Fariss BL; Karpas AE
    J Clin Endocrinol Metab; 1983 Sep; 57(3):645-8. PubMed ID: 6683724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study.
    Dobs AS; Hoover DR; Chen MC; Allen R
    J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.
    Dobs AS; Bachorik PS; Arver S; Meikle AW; Sanders SW; Caramelli KE; Mazer NA
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study.
    Skakkebaek NE; Bancroft J; Davidson DW; Warner P
    Clin Endocrinol (Oxf); 1981 Jan; 14(1):49-61. PubMed ID: 7014044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
    Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
    J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
    Winters SJ; Atkinson L
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.